Severe Ototoxicity in a Health Care Worker Who Received Postexposure Prophylaxis with Stavudine, Lamivudine, and Nevirapine after Occupational Exposure to HIV
Open Access
- 1 February 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 34 (3) , 418-419
- https://doi.org/10.1086/324368
Abstract
Sir—Simdon et al. [1] recently reported 3 cases of ototoxicity that occurred in individuals infected with human immunodeficiency virus (HIV) who were receiving antiretroviral therapy that included nucleoside analogues. We wish to describe a case of severe hearing loss and dizziness that occurred in a health care worker shortly after completion of postexposure prophylaxis (PEP).Keywords
This publication has 7 references indexed in Scilit:
- Ototoxicity Associated with Use of Nucleoside Analog Reverse Transcriptase Inhibitors: A Report of 3 Possible Cases and Review of the LiteratureClinical Infectious Diseases, 2001
- Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy?Current Opinion in Infectious Diseases, 2000
- Steroid-induced invasive aspergillosis with thyroid gland abscess and positive blood culturesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1998
- Hearing loss and antiretroviral therapy in patients infected with HIV-1.Archives of Neurology, 1997
- Irreversible ototoxicity associated with zalcitabineInternational Journal of STD & AIDS, 1997
- Association of Mitochondrial DNA Deletions and Cochlear Pathology: A Molecular Biologic ToolThe Laryngoscope, 1996
- Acoustic neuropathy associated with zalcitabine-induced peripheral neuropathyAIDS, 1993